Reaction Biology Awarded NIH R01 Screening Roadmap Grant
Complete the form below to unlock access to ALL audio articles.
Reaction Biology Corporation, (RBC), has announced that it has been awarded an R01 grant from the National Institutes of Health to accelerate development of its DiscoveryDot™ High Throughput Screening technology for drug discovery.
The NIH grant is part of the Screening Roadmap, designed to produce chemical tools for use in biological research and drug development. Out of 8 recipients of grants pursuant to the original RFA, Reaction Biology is the only private corporation to be so awarded.
The grant provides for $1,828,000 in funding over four years. It originates from the National Human Genome Research Institute and funds two specific areas: 1) The further development of RBC's proprietary spray deposition technology for High Throughput Screening reaction activation, and 2) The development of enhanced microarray printing technology for use in RBC's DiscoveryDot™ HTS system and elsewhere.
RBC claims that, the DiscoveryDot™ technology currently is capable of screening up to 6,600 individual reactions at 1 nanolter volume on a 1-by-3 inch glass slide.
